© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
New treatment approaches target tumors with shared characteristics, regardless of where they appear in the body.
Opdivo will be used to treat hepatocellular carcinoma, which can be caused by hepatitis B or C.
A new type of treatment can slow disease progression in women with advanced breast cancer (ASCO)
Three months of post-surgery chemotherapy worked nearly as well as the standard six-month regimen with substantially less nerve damage.
Disease-free survival was similar for women who became pregnant and those who did not, including among those with ER-positive breast cancer.
Two types of treatment targeting different genetic mutations show promising results in clinical studies.
Risk reduction was most impressive among men, but greater vaccine coverage is needed for maximum impact.
Lynparza (olaparib) was nearly twice as likely as chemotherapy to shrink tumors in women with metastatic breast cancer.
More treatment options may soon become available for those with hepatocellular carcinoma (HCC), which is often diagnosed late.
Two trials show that adding Zytiga to standard treatment for advanced prostate cancer reduces death risk.
Keytruda shows promise in treating an aggressive form of the cancer that occurs more often in younger women, especially young Black women.
Findings from three clinical trials of larotrectinib were presented at this year’s American Society of Clinical Oncology in Chicago.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
